Latest news
Context Therapeutics Inc. Stock 12‑Month Price Target Cut to $4.56, Implies 557% Upside - TradingViewTradingView · Thu, 06 Aug 2026 23:20:13 GMTKey facts: NASDAQ:CNTX to dose CT-202 in Q3'26; shares -30%; $5 target - TradingViewTradingView · Thu, 06 Aug 2026 07:14:59 GMTContext Therapeutics Stock (CNTX) is Falling After Hours: Here's What's Driving the Move - TradingViewTradingView · Thu, 06 Aug 2026 05:32:00 GMTContext Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Wed, 05 Aug 2026 21:44:29 GMTContext Therapeutics Inc. 1H 2026: Net income $(23.24)M, Diluted EPS $(0.24) — 10-Q Summary - TradingViewTradingView · Wed, 05 Aug 2026 20:11:00 GMTCNTX: R&D costs rose sharply as focus shifted to CTIM-76 and CT-202, with cash runway into Q4 2027 - TradingViewTradingView · Wed, 05 Aug 2026 20:10:41 GMTCNTX Q2'26 Earnings: revenue estimate is 0 USD - TradingViewTradingView · Wed, 05 Aug 2026 11:00:33 GMTCNTX: CTIM-76 and CT-202 prioritized; $43M cash funds operations into Q4 2027; net loss rises - TradingViewTradingView · Wed, 05 Aug 2026 07:52:36 GMT